Table 2.

Treatment patterns of nivolumab by age group

	All patients (n=901)	<75 years (n=723)	≥75 years (n=178)	Difference <75 years vs ≥75 years
Treatment line, n (%)
Median (range)	2.0 (1.0–12.0)	3.0 (1.0–12.0)	2.0 (1.0–9.0)
1	38 (4.2)	33 (4.6)	5 (2.8)	0.0666*†
2	422 (46.8)	323 (44.7)	99 (55.6)
3	239 (26.5)	201 (27.8)	38 (21.3)
≥4	202 (22.4)	166 (23.0)	36 (20.2)
Number of doses, median (range)	5.0 (1.0–44.0)	5.0 (1.0–44.0)	5.0 (1.0–43.0)	0.5074†
Treatment duration, median (range)	59.0 (1.0–693.0)	59.0 (1.0–693.0)	70.5 (1.0–602.0)	0.4974†
Patients who continued nivolumab after the study, n (%)	129 (14.3)	101 (14.0)	28 (15.7)	0.5511*

*Fisher’s exact test.

†1 vs 2 vs 3 vs ≥4.